Focus: Nihon Kohden is a public medical electronic equipment manufacturer specializing in cardiovascular, respiratory, and neurology monitoring and diagnostic devices. The company operates from New York headquarters with a portfolio of non-invasive physiological monitoring technologies.
Profile data last refreshed 12h ago · AI intelligence enriched 3w ago
Stable — net +1 jobs in 30d
2 added, 1 removed. Backfill posture.
Best fit for medical device professionals or clinical monitoring specialists; unsuitable for traditional drug development careers due to device-only business model and minimal hiring activity.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Help build intelligence for Nihon Kohden
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from Nihon Kohden's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Nihon Kohden Expands Executive Leadership to Support Continued Growth and Customer Experience - Business Wire
Nihon Kohden Expands Executive Leadership to Support Continued Growth and Customer Experience Business Wire
Nihon Kohden Brings NomadAir With Connect to Dental Sleep Medicine - Medical Product Outsourcing
Nihon Kohden Brings NomadAir With Connect to Dental Sleep Medicine Medical Product Outsourcing
Recon: Lilly to buy psychedelic developer AtaiBeckley for up to $3.8B; FDA approves Merck’s novel cholesterol drug - RAPS
Recon: Lilly to buy psychedelic developer AtaiBeckley for up to $3.8B; FDA approves Merck’s novel cholesterol drug RAPS
Nihon Kohden Upgrades NKV-550, Now First Ventilator Combining Non-Invasive Muscle Pressure Monitoring, AVM and Adjustable AdaptiveSync™ Manufactured in the U.S. - Business Wire
Nihon Kohden Upgrades NKV-550, Now First Ventilator Combining Non-Invasive Muscle Pressure Monitoring, AVM and Adjustable AdaptiveSync™ Manufactured in the U.S. Business Wire
Pilot Study Underway to Evaluate Neuroimmune Modulation Treatment for Multiple Sclerosis - Medical Product Outsourcing
Pilot Study Underway to Evaluate Neuroimmune Modulation Treatment for Multiple Sclerosis Medical Product Outsourcing
United Therapeutics' Liver Assist Product Earns FDA Regenerative Medicine Advanced Therapy Designation - Medical Product Outsourcing
United Therapeutics' Liver Assist Product Earns FDA Regenerative Medicine Advanced Therapy Designation Medical Product Outsourcing
Showing 6 of 10 news items
Based on last 4 crawl cycles
Source: USCIS H-1B Employer Data Hub
Recent peer-reviewed publications with author affiliations at this company
Corrigendum to "Relationship between the diagnostic probability of chronic kidney disease calculated using artificial intelligence-enhanced electrocardiography and the incidence of cardiovascular events" [International Journal of Cardiology 458 (2026) 134576].
Relationship between the diagnostic probability of chronic kidney disease calculated using artificial intelligence-enhanced electrocardiography and the incidence of cardiovascular events.
Showing 5 of 10 publications
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/mo